Revance Therapeutics, Inc.

Revance Therapeutics — Technical Presentation (December 2016)

15 slides from Revance Therapeutics's technical presentation, Dec 12, 2016

  1. Slide 1: RT002 Interim Results for Phase 2 Open-Label Study in Cervical Dystonia

    Revance TherapeutIcs DaxibotulinumtoxinA for Injection (RT002) Investigational Product for the Treatment of Cervical Dystonia RT002 is an investigational product Interim Results for Phase 2 Open-Label Study Exhibit 99.1

  2. Slide 2: Forward-Looking Statements / Safe Harbor

    Forward-Looking Statements / Safe Harbor This presentation contains forward-looking statements, including statements related to: our financial outlook and other financial performance; the process and timing of anticipated future clinical development of our product candidates; our business strategy,

  3. Slide 3: Study Objectives, Primary & Secondary Efficacy Endpoints

    Study Objectives To assess the safety and preliminary efficacy of RT002 for Injection in subjects with isolated CD To evaluate the duration of effect of RT002 for Injection in the treatment of isolated CD Primary Endpoint: Improvement of dystonia, as measured by change from baseline in TWSTRS-Total

  4. Slide 4: Cervical Dystonia Phase 2 Study Design

    Cervical Dystonia (CD) Phase 2 Study Design RT002 up to 200 U Independent Data Monitoring Committee (iDMC) (6 week safety) iDMC (6 week safety) RT002 200 to 300 U RT002 300 to 450 U Eligibility Criteria: Patients with Moderate to Severe CD TWSTRS*-Total score ≥ 20 TWSTRS-Severity subscale ≥ 15 Cohor

  5. Slide 5: Demographics

    Demographics Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Mean age (range) 57 (46--74) 52 (32--70) 58 (30--69) 56 (30--74) Females, n (%) 11 (92%) 8 (67%) 9 (69%) 28 (76%) Mean RT002 dose, U, (range) 174 (100--200) 229 (200--300) 323 (300--450) 244 (100--450) Mean CD Disease Duration,

  6. Slide 6: Treatment-Related Adverse Events

    Treatment-Related Adverse Events ( > 2 Events) Preferred Term Cohort 1 (N=12) Cohort 2 (N=12) Cohort 3 (n=13) All (n=37) Subjects with treatment-related AEs, n (%) 6 (50%) 5 (41.7%) 2 (15.4%) 13 (35.1%) Total number of Treatment-related AEs* 8 8 4 20 Dysphagia 1 (8.3%) 2 (16.7%) 1 (7.7%) 4 (10.8%)†

  7. Slide 7: Mean Baseline TWSTRS-Total Score and Subscales

    Mean Baseline TWSTRS-Total Score and Subscales Error bars represent +1 SE. TWSTRS-Total Score

  8. Slide 8: Primary Endpoint: Reduction in TWSTRS-Total Score at Week 4 by Cohort

    Primary Endpoint: Reduction in TWSTRS-Total Score at Week 4 by Cohort NOTE: 1) Two subjects currently on study had missing value at Week 4 for IA 38% 46% 28% 41% Clinically Meaningful Reduction in TWSTRS-Total Score Observed at Week 4 across all 3 Cohorts

  9. Slide 9: Secondary Endpoint: Change from Baseline in TWSTRS-Total Score over Time

    Secondary Endpoint: Change from Baseline in TWSTRS-Total Score over Time 46% 43% 33% 28% 51% 27% 41% Clinically Meaningful Reduction in TWSTRS-Total Score Observed by Week 2 and Maintained to Week 24 for Cohort 1* 36% * Later-enrolled subjects in the second and third cohorts have yet to complete the

  10. Slide 10: Secondary Endpoint: Duration of Response

    Median Duration Cohort 1 >24 weeks Cohort 1+2 >24 weeks* Cohort 2 Censored at 16 weeks *Cohort 1+2 analysis based on worse-outcome imputation for ongoing subjects Note: 1) Study discontinuation prior to Week 24 counted as an event. 2) Analysis for Cohort 2 censored at Week 16 as portion of subjects

  11. Slide 11: Reduction in TWSTRS-Total Score and Subscales at Week 4

    Primary & Secondary Endpoints: Reduction in TWSTRS-Total Score and Subscales at Week 4 NOTE: Subjects with a missing value for either Baseline or Week 4 are excluded from the summary. 38% 34% 42% 41% Clinically Meaningful Reduction Observed across all 3 TWSTRS Subscales at Week 4

  12. Slide 12: Secondary Endpoint: Proportion of Responders with Improvement in CGIC

    Secondary Endpoint: Proportion of Responders with Improvement in CGIC* (Score >0) by Visit * Clinician Global Impression of Change At Least 70% Response Rate at Week 16 Observed in Cohorts 1 and 2, with majority of benefit maintained in Cohort 1 subjects at Week 24 Note: Based on observed data only

  13. Slide 13: Secondary Endpoint: Change from Baseline in CDIP-58 over Time

    Secondary Endpoint: Change from Baseline in CDIP-58* over Time 25% 24% 41% 33% 30% 45% 32% * Cervical Dystonia Impact Profile-58 Quality of Life Measure Meaningful Improvement in Patient Rated Quality of Life Observed at Week 4, with Majority of Benefit Maintained in Cohort 1 at Week 24 Note: Based

  14. Slide 14: Summary of Safety Results

    Summary of Safety Results RT002 appeared to be generally safe and well tolerated across all 3 cohorts, with no increase in treatment-related AE’s upon dose escalation Total of 20 Treatment Related AE’s reported in 13 of 37 subjects Most frequently reported: dysphagia (10.8%), injection site erythema

  15. Slide 15: Summary of Efficacy Results

    Summary of Efficacy Results Clinically meaningful treatment benefit addressing the disabling features of CD was observed in the TWSTRS-Total Score, with a mean reduction of 38% across all subjects at Week 4 In Cohort 1, with a mean dose of 174U, the majority of the treatment benefit observed at Week

Revance Therapeutics — Technical Presentation (December 2016) on 6ix